US Edition
BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute
- BioNTech announced on Thursday it will acquire CureVac in a $1.25 billion all-stock deal to combine their mRNA technologies in Germany.
- The acquisition follows three years of litigation over mRNA patent infringement, with CureVac suing BioNTech in 2022 and courts upholding CureVac patents.
- BioNTech will integrate CureVac’s mRNA platforms and manufacturing to enhance oncology research and accelerate cancer immunotherapy development.
- Each CureVac share will convert to about $5.46 in BioNTech shares, a 55% premium, valuing CureVac at $1.25 billion and giving CureVac shareholders 4%-6% of BioNTech.
- The deal, expected to close in 2025 pending regulatory approvals, supports BioNTech’s oncology strategy while potentially resolving costly patent royalty risks.
71 Articles
71 Articles
BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute
BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy candidates. Analysts say the M&A deal is a way to essentially settle out of court the ongoing mRNA patent dispute between the companies following some recent CureVac legal wins. The post BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute appeared first on MedCity News.
The German company Biontech, which has become world famous with a Corona vaccine, wants to buy its competitors in Tübingen. The bundling of the forces is to create a biotech champion.
derwesten.de
Stock hammers around Biontech and Curevac! There is a spectacular takeover in billions.
Once they were both considered to be large biotech hope carriers, they delivered a head-to-head race at the Corona vaccine, arguing for patents. Now Biontech from Mainz is reaching for Curevac from Tübingen.
Once they were both considered to be large biotech hope carriers, they delivered a head-to-head race at the Corona vaccine, arguing for patents. Now Biontech from Mainz is reaching for Curevac from Tübingen.
Coverage Details
Bias Distribution
- 46% of the sources are Center
To view factuality data please Upgrade to Premium
